News - Page 177 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

Post published:May 25, 2021
Post category:Press Release

Read more about the article Silo Pharma Submits Application for NASDAQ up-listing

Silo Pharma Submits Application for NASDAQ up-listing

Post published:May 25, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Partners with Alcami for Proprietary Formulations

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

Post published:May 25, 2021
Post category:Press Release

Read more about the article MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System

MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System

Post published:May 24, 2021
Post category:Press Release

Read more about the article MagicMed to Be Acquired by Nasdaq-Listed Company

MagicMed to Be Acquired by Nasdaq-Listed Company

Post published:May 24, 2021
Post category:Analysis News

Read more about the article Psychedelic Bulletin: CB Therapeutics’ Biosynthesis Patent; MindMed to Explore Mescaline; BBC Documentary Highlights Psilocybin

Psychedelic Bulletin: CB Therapeutics’ Biosynthesis Patent; MindMed to Explore Mescaline; BBC Documentary Highlights Psilocybin

Post published:May 22, 2021
Post category:Psychedelic Bulletin

Read more about the article Wesana Health Expands Research Leadership Team with Mark Wingertzahn, PhD as Chief Scientific Officer

Wesana Health Expands Research Leadership Team with Mark Wingertzahn, PhD as Chief Scientific Officer

Post published:May 21, 2021
Post category:Press Release

Read more about the article Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Post published:May 20, 2021
Post category:Press Release

Read more about the article Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs

Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs

Post published:May 20, 2021
Post category:Press Release

Read more about the article Former Senate Majority Leader Tom Daschle Appointed Special Adviser to Field Trip Health Ltd.

Former Senate Majority Leader Tom Daschle Appointed Special Adviser to Field Trip Health Ltd.

Post published:May 20, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.